You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.
At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.
FibroGen plans follow-on offering of common stock
COVID-19 Pandemic Likely To Cause US Telemedicine Boom
Gauging Supply Chain Risk In Volatile Times
Cannabis: Hashing Out a Budding Industry
IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help
FibroGen Inc. plans to offer and sell up to $300 million of its common stock in an underwritten follow-on offering.
The company expects to grant the underwriters an option to buy additional common shares.
Net proceeds will be used to fund the expansion of product development, manufacturing and commercialization activities as well as for general corporate purposes.
Goldman Sachs & Co. LLC, Citigroup and Leerink Partners LLC are acting as joint book-running managers for the offering.